A method to assess the dissipation of residual hypnotics: Eszopiclone versus zopiclone by Boyle, J et al.
A Method to Assess the Dissipation of the Residual Effects of Hypnotics: 
Eszopiclone versus Zopiclone. 
 
Julia Boyle (PhD),1 John A. Groeger (PhD),2,3 Walter Paska (PhD),4 James A. Cooper 
(PhD),5 Carol Rockett (PharmD),6 Sion Jones (PhD),4 Paul Gandhi (Mrcpsych),5 
Jenny Scott (MSc),4 Giuseppe Atzori (MSc)1,Derk-Jan Dijk (PhD)1,3  
1Surrey Clinical Research Centre, Faculty of Health & Medical Sciences, University 
of Surrey, Guildford, Surrey, UK 
2Department of Applied Psychology, University College Cork, Ireland 
3Surrey Sleep Research Centre, Faculty of Health & Medical Sciences, University of 
Surrey, Guildford, Surrey, UK 
4GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, UK  
5GlaxoSmithKline, Brentford, Middlesex, UK 
6GlaxoSmithKline, Research Triangle Park, N.C., USA 
Corresponding author: Julia Boyle BSc (Hons) PhD 
Director of Surrey CRC 
Division of Clinical Medicine 
Faculty of Health & Medical Sciences 
University of Surrey 
Guildford 
Surrey 
GU2 7XP 
J.Boyle@surrey.ac.uk 
Tel +44 (0)1483 689783 
Fax +44 (0)1483 689790 
 
Conflicts of Interest and Source of funding: Julia Boyle has received research 
support from GlaxoSmithKline, Merck&Co Inc and Pfizer Ltd.  
John A. Groeger has received research support from GlaxoSmithKline, H Lundbeck 
A/S, Merck & Co Inc and has served as consultant for Glaxo-Smith Kline, H 
Lundbeck A/S, Merck&Co Inc.     
Derk-Jan Dijk has received research support from GlaxoSmithKline, H Lundbeck 
A/S, Merck&Co Inc, Philips Lighting, Organon, Takeda, Wellcome Trust and has 
served as consultant for Actelion, Cephalon, Glaxo-Smith Kline, Lilly, H Lundbeck 
A/S, Merck&Co Inc., Metronaps, Ono Pharmaceuticals, Pfizer Inc, Philips Lighting, 
Sanofi Aventis, Takeda.  
James Cooper, Carol Rockett, Paul Gandhi, Sion Jones and Jenny Scott, are 
employees of GlaxoSmithKline.  
Walter Paska was an employee of GSK at the time of study conduct.  
For the remaining authors none were declared. 
Scientists and biostatisticians at GlaxoSmithKline, which sponsored the study, 
described in this manuscript, collaborated with study investigators in study design, 
data analysis, interpretation of the results, preparation of the manuscript, and the 
decision to submit the manuscript for publication.  Statistical analyses were conducted 
at GlaxoSmithKline. 
Running title: Eszopiclone next-day impairment profile. 
Funding: The study was funded by GlaxoSmithKline. 
A Method to Assess the Dissipation of the Residual Effects of 
Hypnotics: Eszopiclone versus Zopiclone. 
 
 Introduction 
The adverse personal and economic consequences of insomnia, which affects 
an estimated 1 in 5 adults worldwide 1, are well established 2. There is consistent 
evidence that insomnia is often coexistent with psychiatric disorders such as 
depression and anxiety 3, as well as emerging evidence that a bidirectional relationship 
may exist 4. 
 
Insomnia is treated primarily with hypnotics that, while generally well tolerated, can 
be associated with side effects potentially as detrimental as insomnia itself. In 
particular, residual sedation (the “hangover” effect), which constitutes prolongation of 
the drugs’ hypnotic effect, results in daytime sleepiness, impairment of psychomotor 
and cognitive functioning 5 and increased risk of injury and accidents 6. 
 
The two compounds under investigation, zopiclone and eszopiclone, are non-
benzodiazepine hypnotics prescribed in the treatment of both transient and short-term 
insomnia and often for its chronic variant.  Zopiclone, a cyclopyrrolone class racemic 
mixture of two steroisomers of which only one is active, was introduced in the second 
half of the eighties and has been proven to be an effective hypnotic, it has however 
been shown to impair next-day functioning 7.  
 
The single-isomer hypnotic eszopiclone [(S)-zopiclone] is a short-acting non-
benzodiazepine insomnia medication. As the active isomer of racemic zopiclone, 
eszopiclone is effective at less than half the dose of racemic zopiclone 8.  In addition, 
exposure to eszopiclone 3.5 mg, a similar concentration of the (S)-isomer contained in 
7.5 mg  zopiclone, has an earlier time to peak concentration (Tmax 1.0 hr compared 
with racemic zopiclone 1.5 hr), and significantly less exposure to active metabolites,  
which may explain  the difference of the two compounds on their residual effect 
profile 9.  
 
The pharmacokinetic profile of eszopiclone, therefore could potentially reduce 
residual-effects, and in randomised, double-blind, placebo-controlled studies in 
healthy volunteers and patients with primary insomnia, cognitive function and 
psychomotor function were not impaired the morning after 3 mg eszopiclone 
compared with placebo 10. However, whilst a proportion of patient studies have 
reported improved subjective ratings of daytime alertness, there was evidence that, 
subjective daytime alertness and ability to function was reduced at the 3mg dose 11. 
 
Eszopiclone has been compared with placebo in studies of next-day residual effects.  
However, it has not been previously compared with racemic zopiclone in a head-to-
head study evaluating next-day psychomotor and cognitive effects. The study reported 
herein was conducted to compare the effects of a single bedtime dose of eszopiclone 
(3 mg) on next-day psychomotor and cognitive function with those of zopiclone (7.5 
mg) and placebo in healthy volunteers. Unlike previous studies of residual effects, 
which assessed for impairment after at least 8 hours of sleep10, the present study used 
a sleep-restriction protocol that limited sleep duration to 7 hours in order to 
approximate real-life circumstances 12. The dissipation of residual effects after the 
sleep episode was assessed with high temporal resolution (at half hourly intervals) 
from 15 minutes to 255 minutes after wake time to include the period characterized by 
sleep inertia during which residual effects are expected to be most evident 13.    
 
Materials and Methods 
Participants 
Medical and psychiatric history; physical examination and serum chemistry, 
hematology, and urinalysis results determined the inclusion of 25 to 40-years old 
participants of both sexes who had provided informed written consent.  Exclusion 
criteria included pregnancy, lactation, ineffective contraception; signs and symptoms 
of a sleep disorder or irregularity; weight <50 kg or BMI <18 or >30; history of 
substance abuse or dependence; smoking >5 cigarettes/day; consuming >300 mg 
xanthinated products or more than 3 to 4 units (men) or 2 to 3 units (women) of 
alcohol (UK government guidelines; daily units); use of prescription or OTC 
psychotropic medications (excluding the occasional use of some cold, flu, or allergy 
remedies containing antihistamines and opiates) in the 3 months before screening; and 
any other medication within 2 weeks before screening. A wrist-mounted actigraphy 
device (Actiwatch AW, CamNtech Ltd, Camdridge UK) aided assessment of ongoing 
eligibility throughout screening, treatment sessions, and washout periods. Further, 
alcohol breath tests and urine tests for drugs of abuse were administered throughout 
the study to ensure compliance.  
 
Procedures 
This was a randomised, double-blind, double-dummy, placebo-controlled, 3-way 
crossover study (GlaxoSmithKline protocol ESZ111503) , comparing  a single 
bedtime dose of 3 mg of eszopiclone with 7.5 mg of  zopiclone and placebo relative to 
next-day psychomotor and cognitive function in healthy adults. The protocol was 
approved by an independent ethics committee (Brent Medical Ethics Committee, 
Harrow, UK). The study was conducted at a single UK site in accordance with "good 
clinical practice" (GCP); the European Union clinical trials directive, 2004; and the 
guiding principles of the Declaration of Helsinki. The study was registered with 
clinicaltrials.gov, identifier: NCT00699608. 
  
The 7- to - 28 day screening period included a clinical visit and 1-night 
polysomnography (PSG) recording. Upon satisfactory eligibility criteria participants 
returned to the clinic after a further 2 to 21 days and were randomised in balanced 
order to 3 crossover treatment sessions during which they received 3 mg eszopiclone, 
7.5 mg zopiclone, or placebo (1 randomised treatment in each crossover session). 
Each treatment session comprised two consecutive days of admission to the study 
clinic for completion of multiple next-day assessments of psychomotor and cognitive 
function following dosing at 10:45 PM with single-blind placebo on Night 1 and 
double-blind study medication on Night 2. Next-day assessments were completed on 
Day 2 (baseline) and Day 3 (post-treatment), respectively. Lights-out was at 11:00 
PM, and sleep time was restricted to 7 hours (11:00 PM to 6:00 AM) in order to 
approximate real-life circumstances and to assess the time course of residual effects. 
A safety follow-up visit was scheduled 7±1 days after the last treatment session. 
 
Measures  
Cognitive and psychomotor measures included: Continuous Tracking Test (CTT) 14, 
Critical Flicker Fusion (CFF) 15, DSST 16, N-backs (1-back and 3-back) 17, and Linear 
Analogue Rating Scales (LARS) 18. Testing commenced at 06:15, 15 minutes after 
awakening (7.5 hours post-dose). The primary comparison of interest was the 
difference between eszopiclone 3 mg and zopiclone 7.5 mg on the CTT mean tracking 
error averaged over 5 assessments:  7.5, 8, 8.5, 9, and 9.5 hours postdose. Secondary 
endpoints were assessed in the morning at 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 
hours after double-blind dosing, including CTT mean tracking error and mean 
reaction time; CFF mean threshold frequency, DSST total of attempted substitutions 
and total of correct substitutions; N-back percentage of correct responses and reaction 
time; and LARS subjective estimates of sedation, mood and coordination. 
 
Data Analysis 
Data on psychomotor and cognitive test performance were analyzed for all 
participants who received at least 1 dose of double-blind study medication (Intention-
to-treat, ITT population). Analyses of covariance (ANCOVA) techniques were used 
to analyse the primary and secondary endpoints. The model for the primary endpoint 
included fixed-effect terms of participants’ baseline, adjusted period-specific baseline, 
age, gender, treatment, and period. Subject was included as a random effect. The 
individual time points were analysed using a repeated-measures model with 
interactions of time-point*treatment, time-point*subject level baseline, and time- 
point*period-specific baseline, in addition to the core covariates used in the primary 
model.  Point estimates for the mean differences with corresponding 95% confidence 
intervals (CIs) were calculated. The associated P-values were provided for 
eszopiclone 3mg versus zopiclone 7.5mg as well as each treatment versus placebo. No 
adjustment for multiplicity was done. 
 
Error diagnostics from residuals were examined to ensure the assumptions of the 
model were valid. Assumptions of normality and homogeneity of variance underlying 
the ANCOVA model were violated, i.e. non-normal residuals and non-constant 
variance. Therefore transformations of the primary endpoint and nonparametric 
methods were applied to assess the robustness of the analysis. The ANCOVA model 
assumptions were violated for the N-back percentage of correct responses; therefore, a 
a priori rank transformation was applied to the data. 
To aid interpretation of the clinical relevance of the findings, a post hoc evaluation of 
standardised differences for the reciprocal-transformed and rank-transformed primary 
endpoint was performed. Post hoc evaluations of standardised differences were also 
completed for the secondary endpoints.  Standardised differences were calculated for 
three 1-hourly assessment phases corresponding to early morning (7.5 to 8.5 hours 
postdose), mid-morning (9 to 10 hours postdose), and late morning (10.5 to 11.5 
hours postdose).  
 
Tolerability 
Tolerability was considered as the percentage of participants with adverse events 
(AE) or serious adverse events (SAE) during the double-blind treatment period, i.e. 
the time of receiving double-blind study medication on Night 2 until midnight of the 
next day, which was Day 3. This followed the European Medicine Authority 
definition for AE and SAE 19 Adverse-event data were summarised with descriptive 
statistics for the ITT population. Other safety measures included vital signs, clinical 
laboratory assessments, and physical examinations at the screening and follow-up 
visits as well as regular pregnancy testing. 
 
Results 
Sample 
Ninety-one participants were randomised to treatment and received at least 1 dose of 
double-blind study medication. Four of the 91 participants prematurely withdrew 
from the study because of non-study commitments, 1 for the protocol violation of a 
positive alcohol-breath test, and 1 because of AEs. Participants were White (69%); 
Black (15%), Asian (15%). Mean age was 29.8 years (SD=3.9), and 51% were 
female. Mean BMI was 23.9 (SD=2.9).  
Primary Endpoint 
Primary Analysis 
Eszopiclone (3 mg) did not differ significantly from zopiclone (3.75 mg eszopiclone) 
on the primary endpoint, i.e. CTT mean tracking error; average of the first 5 
assessments on Day 3, [eszopiclone (3 mg) versus zopiclone (7.5 mg) – 0.99 pixels, 
95% CI – 2.74 to 0.76, P=0.267]. Both active treatments significantly differed from 
placebo (eszopiclone versus placebo: 2.20 pixels, 95% CI 0.45 to 3.96, P=0.014; 
zopiclone versus placebo: 3.19 pixels, 95% CI 1.46 to 4.93, P<0.001) (Figure 1). 
Post Hoc Analyses of the Primary Endpoint 
Parametric ANCOVA analysis of the reciprocal-transformed endpoint yielded a 
statistically significant difference favoring eszopiclone (3 mg) over zopiclone (3.75 
mg eszopiclone; P=0.026) as well as statistically significant differences between each 
active treatment and placebo (P<0.001). A nonparametric rank-transformed analysis 
yielded results consistent with the parametric reciprocal-transformed analysis, but the 
difference between eszopiclone and zopiclone did not reach statistical significance at 
the 5% level (P=0.061). In the post hoc analysis of standardised differences for the 
reciprocal-transformed and rank-transformed primary endpoint, small but potentially 
clinically relevant differences of 0.30 and 0.24, respectively, were observed in favour 
of eszopiclone over zopiclone.   
Secondary Endpoints 
The secondary endpoints (Figure 1] were broadly consistent with those for the 
primary endpoint. Numerical trends favoring eszopiclone over zopiclone were 
generally observed, but in the majority of cases fell short of statistical significance. 
The N-back test differentiated eszopiclone from zopiclone most clearly and 
consistently (Figure 2). Trends toward improvement in performance as time since 
waking increased were observed for the DSST number attempted and number correct, 
and LARS sedation (Figure 3). 
 
Post hoc analyses of standardised differences on the secondary endpoints, revealed 
small but potentially clinically relevant standardised differences (≥0.20) favouring 
eszopiclone (3mg) over zopiclone (3.75mg eszopiclone) for 7 of the 14 endpoints 
during the early phase of the morning (CTT mean tracking error, CTT reaction time, 
1-back and 3-back percentage of correct responses, 3-back reaction time, LARS 
sedation, and LARS coordination); 1 of 14 endpoints during the middle phase (1-back 
percentage of correct responses), and 3 of 14 endpoints during the late phase of the 
morning (CTT mean tracking error, 3-back percentage of correct responses, and 
LARS sedation, Figure 3).  
 
 
Adverse Events 
The proportion of participants with at least 1 AE was 50% with eszopiclone, 49% 
with zopiclone, and 13% with placebo. The most common AEs were dysgeusia and 
somnolence (Table 1). No SAEs were reported. One participant prematurely withdrew 
from the study because of AE. This participant, a 25-year-old female, reported 
feelings of fear and hallucinations, both events began 26 minutes after a dose of 
eszopiclone in the second crossover period. The fear event lasted for 39 minutes, and 
the hallucination event lasted for 6 minutes. Both events were of moderate severity. 
The investigator deemed these adverse events to be drug related. 
  
Discussion 
Next-day residual impairment constitutes a significant problem with many hypnotics. 
In experimental studies in healthy volunteers, hypnotics cause sedation and impair 
psychomotor function, attention, and memory the day after bedtime use 6 and in 
epidemiologic studies, hypnotics are associated with increased risk of traffic accidents 
20. One of the outcomes of the development of eszopiclone was the assertion that the 
compound improved upon the next-day residual-effect profiles of other insomnia 
medications including its racemate parent zopiclone. To assess the veracity of this 
claim this randomised, double-blind, placebo-controlled head-to-head study compared 
eszopiclone (3 mg) with zopiclone (3.75 mg eszopiclone) in a protocol designed to 
quantify the time course of residual effects after mild sleep restriction in healthy 
volunteers, i.e.7 hours of time in bed for 2 consecutive nights.  
 
Compared with placebo, both eszopiclone (3 mg) and zopiclone (3.75 mg 
eszopiclone) were associated with next-day residual effects that were most severe 
shortly after awakening , dissipated over time but remained significant for several 
hours after awakening. Some differentiation between the compounds was observed, in 
particular for tasks that had a high demand on executive resources (3-back) rather 
than the less demanding tasks of sensori-motor performance. Interestingly there were 
indications of smaller residual effects with eszopiclone (3 mg) compared with  
zopiclone (3.75 mg eszopiclone) across a range of tests including the CTT, DSST, the 
N-back  (1- and 3-back), and the LARS (sedation and coordination scores). 
 
The difference between eszopiclone (3 mg) and zopiclone (7.5 mg) was not 
statistically significant on the primary endpoint. Transformation of the primary 
endpoint and ranked analysis in accordance with a priori stipulations, demonstrated 
differences between eszopiclone and zopiclone that were either statistically significant 
or approached statistical significance in favour of eszopiclone, however both 
compounds differed significantly form placebo. Previous studies in patients with 
primary and coexistent insomnia have shown that eszopiclone was consistently 
associated with improvements in daytime functioning, subjective alertness and health-
related quality of life 21, 7. Also a study with healthy participants and primary 
insomnia patients using a comprehensive battery of psychometric tests and car driving 
ability did not demonstrate residual impairment, however testing for residual 
impairment did not begin earlier than 9.75 hr post-dose 13. The mild sleep restriction 
protocol used in this study proved an effective tool for demonstrating residual 
impairment.  Time constraints limited the number of cognitive assessments that could 
be made and did not allow inclusion of vigilance type tests, such as the psychomotor 
vigilance task. 
 
This study is, to the authors’ knowledge, the first well-controlled study attempting to 
characterise thoroughly the time course of residual effects of insomnia medications 
using a sleep-restriction protocol approximating real-life circumstances and assessing 
the time course of residual effects. Previous studies assessing next-day effects of 
eszopiclone allowed at least 8 hours of sleep 9, 13.  Whether a similar residual effect 
profile would be observed if a sleep period of 8 hrs was allowed in a study with 
primary insomnia patients, is unclear as healthy volunteers are typically more 
sensitive to residual effects.  In addition, subtle deficits in cognitive performance have 
been observed in insomnia patients, particularly attention based tasks with high 
cognitive load 21 and therefore a complex interaction between performance 
enhancement and residual impairment may occur in patient populations.  
 
The AE profile of eszopiclone in this study is consistent with previous findings in 
healthy volunteers and patients with primary insomnia 9. The incidence of specific AE 
was similar between eszopiclone and zopiclone. No new safety or tolerability findings 
were noted. 
 
In summary, previous research has shown that eszopiclone is an effective hypnotic 
medication on short or long-term administration with no evidence of tolerance.  This 
study is the first to examine the time course of the residual effect profile of 
eszopiclone, zopiclone and placebo following a sleep restriction protocol.  The study 
showed that both eszopiclone (3 mg) and zopiclone (3.75 mg eszopiclone) compared 
with placebo caused statistically and clinically relevant next-day residual effects that 
continued for several hours after awakening. The data indicated these effects were 
typically smaller in magnitude for eszopiclone, and did not persist to the same extent, 
although these may have been a function of the smaller dose of eszopiclone.  
As with many hypnotics, however, patients should be cautious when driving a 
vehicle, or operating machinery the day after ingestion.  
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Figure 2. 1-Back and 3-Back Memory Tests: Percentage of Correct Responses.  
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Figure 3. Post Hoc Analysis of Standardised Differences.  
 
Early Morning
-2.0 -1.6 -1.2 -0.8 -0.4 0.0 0.4 0.8 1.2 1.6 2.0
LARS coordination
LARS mood
LARS sedation
3-Back reaction time
1-Back reaction time
3-Back correct responses (rank transformed)
1-Back correct responses (rank transformed)
DSST number of correct responses
CFF overall mean
CTT reaction time
CTT mean tracking error (reciprocal)
Mid Morning
LARS coordination
LARS mood
LARS sedation
3-Back reaction time
1-Back reaction time
3-Back correct responses (rank transformed)
1-Back correct responses (rank transformed)
DSST number of correct responses
CFF overall mean
CTT reaction time
CTT mean tracking error (reciprocal)
Late Morning
Standardised Difference
-2.0 -1.6 -1.2 -0.8 -0.4 0.0 0.4 0.8 1.2 1.6 2.0
LARS coordination
LARS mood
LARS sedation
3-Back reaction time
1-Back reaction time
3-Back correct responses (rank transformed)
1-Back correct responses (rank transformed)
DSST number of correct responses
CFF overall mean
CTT reaction time
CTT mean tracking error (reciprocal)
Treatment vs Placebo
  
 
 
Table 1. Adverse Events Reported During Double-Blind Treatment (Night 2 
Through Midnight on Day 3). Adverse events reported in ≥2% of participants 
with any treatment in the ITT population are listed. 
 
 Eszopiclone 
(n=88) 
Racemic 
Zopiclone 
(n=90) 
Placebo 
(n=89) 
N (%) 
Dysgeusia 27 (31) 30 (33) 0 (0) 
Somnolence 11 (13) 7 (8) 1 (1) 
Fatigue 6 (7) 6 (7) 4 (4) 
Nausea 4 (5) 4 (4) 3 (3) 
Dizziness 4 (5) 5 (6) 0 (0) 
Headache 2 (2) 2 (2) 2 (2) 
Disturbance in attention 2 (2) 3 (3) 0 (0) 
Hallucination 2 (2) 0 (0) 0 (0) 
Nightmare 2 (2) 0 (0) 0 (0) 
Rash 2 (2) 0 (0) 0 (0) 
 
Figure Legends 
 
Figure 1.  Adjusted means (SEM) for CTT mean tracking error in pixels 
(untransformed data). Data for the placebo and zopiclone condition were displaced 
along the x-axis to avoid data points being obscured.  Values plotted at the mean time 
point are the primary endpoint and reflect the mean of the first 5 time points post 
dose.   
 
Figure 2. Adjusted means (SEM) for N-back percentage correct at each time point on 
Day 3 on the 1-back task (panel A) and the 3-back task (panel B) (untransformed 
data). Placebo (), eszopiclone 3 mg (○) and zopiclone 7.5 mg (▼). 
 
Figure 3. Early-morning, middle-morning, and late-morning standardised differences 
(95% CIs) between eszopiclone (○) and placebo, and racemic zopiclone (●) and 
placebo for secondary endpoints. A standardised difference <0 reflects impairment of 
waking performance following treatment compared with placebo. The more negative 
the standardized difference the greater the impairment.  A standardized difference of 
0.2 – 0.5 reflects a small size effect, 0.5 – 0.8 a medium effect and >0.8 a large effect 
size.  Significance cannot be determined from whether or not 0 is included within the 
CI.  
  
 
